Oakwood Medical Investors V

Portfolio Companies

Advanced Pain Management is the largest single-specialty, pain management group in the country, with more than 26 board-certified interventional pain physicians performing the most advanced interventional pain management procedures available to patients suffering primarily from chronic neck and back pain in an ASC setting.  APM's physicians operate out of more than 35 locations in Wisconsin and Minnesota and execute 140,000 patient encounters annually. 

Aptus Endosystems, Inc. is developing advanced technologies for the endovascular treatment of aortic aneurysms. Aptus Endosystems has developed a novel, proprietary EndoStapling technology that, combined with a uniquely designed endograft, creates the opportunity to perform an endovascular repair procedure that better approximates traditional open surgical repair. 

Caprion Proteomics, Inc. is a leading provider of integrated proteomic biomarker and target identification solutions and advanced immune monitoring services to pharmaceutical and biotechnology companies as well as government research organizations.  Caprion's key services include: biomarker discovery, biomarker validation, drug target discovery, immune monitoring services and clinical diagnostic product development.

EMKinetics, Inc. is developing neuromodulation therapies based on its Transdermal Stimulation (TranStim™) technology. The EMKinetics technology focuses on neuromodulation for the treatment of overactive bladder and other maladies.

Hygieia, Inc. is developing the d-Nav™, a Diabetes Insulin Guidance System (DIGS™). The d-Nav DIGS handheld device replaces a patient's existing glucose meter and provides individually tailored insulin dosage recommendations between physician visits to result in improved glycemic control.

Lanx, Inc. specializes in systems and implants for all segments of spinal surgery.  Integrating leading technology, intellectual property and state-of-the-art engineering, each product is designed to simplify surgery and improve the quality of care for patients worldwide by providing surgeons with innovative spinal products.

Mitralign, Inc. is developing an innovative, catheter-based method to effectively treat mitral regurgitation in patients suffering from Congestive Heart Failure. Mitralign's goal is to emulate the technique employed in traditional open heart surgical repair but in a far less invasive manner.